Oppenheimer raised the firm’s price target on Neurocrine (NBIX) to $230 from $220 and keeps an Outperform rating on the shares. The firm’s conviction in Neurocrine strengthened following impressive Q1 results with both Ingrezza and Crenessity outperforming expectations, while key pipeline progress remains underappreciated.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Evan Seigerman Maintains Hold on Neurocrine as Strong Commercial Execution Drives Price Target Increase to $144 Amid Strategic Uncertainty
- Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks
- Neurocrine Remains Top Pick on Durable Multi‑Year Growth Outlook; Buy Rating Reiterated with Unchanged $200 Price Target
- Neurocrine Biosciences Delivers Record Quarter, Eyes 2027
- Ami Fadia Reiterates Buy on NBIX After Strong 1Q26 Beat and Robust Ingrezza and Crenessity Demand